Track the Canadian Junior Mining Market at the speed of AI

Build a portfolio of Canadian junior mining companies on 6ix and get real-time updates the minute they announce something. Discover investor events, company profiles, and news in one place.

Please enable JavaScript to use all features of 6ix.com.

Latest Press Releases

Time	Headline
51m ago	The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
51m ago	Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
51m ago	Max Power Mining Closes $25 Million Strategic Investment From Eric Sprott To Accelerate Commercial Evaluation at Lawson Max Power Mining Corp
1h ago	Mach Travel Solutions Delivers Sustained FY26 Performance Despite Challenging Macro- Economic Environment; While Accelerating Transformation into an Integrated Travel Solutions Platform Mach Conferences And Events Ltd.
2h ago	Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform Vanta Holdings Inc.

About

1.38USD+0.00 +0.00%

Closed • Updated at 04:51 GMT+00:00

Market Cap$99.77M

Volume516.7K

Beta3.00

RSI44.23

Health TechnologyPharmaceuticals: Major

Biomea Fusion, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Recent Videos

This $1.50 Biotech Stock Could Explode If Shorts Are Wrong

This $1.50 Biotech Stock Could Explode If Shorts Are Wrong

May 13, 2026

BMEA STOCK : POTENTIAL BOUNCEBACK | BIOMEA FUSION STOCK

BMEA STOCK : POTENTIAL BOUNCEBACK | BIOMEA FUSION STOCK

May 10, 2026

Type 1 Diabetics See Significant Improvement with Icovamenib #type1diabetes #treatment

Type 1 Diabetics See Significant Improvement with Icovamenib #type1diabetes #treatment

May 07, 2026

"This Drug Boosted Insulin Production by 52% — And It Lasted a Full Year."

"This Drug Boosted Insulin Production by 52% — And It Lasted a Full Year."

May 06, 2026

Community Chat

Ask AI

Try asking